| Group VE (n = 49) | Group E (n = 363) | Group Y (n = 384) | p; VE vs. E | p; VE vs. Y |
---|---|---|---|---|---|
Recurrence cases (%) | 49 (24) | 64 (231) | 68 (261) | 0.04 | < 0.01 |
Median recurrence duration (months) (range) | 11 (3–68) | 11 (0.4–111) | 9 (0.2–197) | 0.98 | 0.39 |
Recurrence site | (n = 24) | (n = 231) | (n = 261) | Â | Â |
 Liver (%) | 75 (18) | 83 (192) | 82 (213) | 0.32 | 0.42 |
 Lung (%) | 33 (8) | 18 (41) | 29 (75) | 0.06 | 0.63 |
 Adrenal glands (%) | 8 (2) | 2 (5) | 5 (14) | 0.07 | 0.54 |
 Bone (%) | 13 (3) | 11 (25) | 10 (27) | 0.80 | 0.74 |
Treatment for recurrence | (n = 24) | (n = 231) | (n = 261) | Â | Â |
 Rehepatectomy (%) | 0 (0) | 6 (15) | 46 (119) | 0.19 | < 0.01 |
 Liver transplantation (%) | 0 (0) | 0 (0) | 3 (8) | - | 0.38 |
 RFA/MCT (%) | 33 (8) | 25 (57) | 18 (46) | 0.35 | 0.06 |
 TACE (%) | 63 (15) | 52 (121) | 47 (122) | 0.34 | 0.13 |
 Resection of metastases (%) | 13 (3) | 3 (7) | 5 (13) | 0.02 | 0.12 |
 Systemic chemotherapy including molecular target drug (%) | 17 (4) | 23 (53) | 33 (85) | 0.48 | 0.10 |
 Radiation (%) | 17 (4) | 12 (27) | 16 (43) | 0.47 | 0.98 |